These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30333454)

  • 1. Flow and volume response to bronchodilator in patients with COPD.
    Vigna M; Aiello M; Bertorelli G; Crisafulli E; Chetta A
    Acta Biomed; 2018 Oct; 89(3):332-336. PubMed ID: 30333454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measures of bronchodilator response of FEV
    Torén K; Bake B; Olin AC; Engström G; Blomberg A; Vikgren J; Hedner J; Brandberg J; Persson HL; Sköld CM; Rosengren A; Bergström G; Janson C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():973-980. PubMed ID: 28356729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease.
    Chhabra SK; Bhatnagar S
    Indian J Chest Dis Allied Sci; 2002; 44(2):91-7. PubMed ID: 12026258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease.
    Walker PP; Calverley PM
    COPD; 2008 Jun; 5(3):147-52. PubMed ID: 18568838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bronchodilator responsiveness and reported respiratory symptoms in an adult population.
    Tan WC; Bourbeau J; Hernandez P; Chapman KR; Cowie R; FitzGerald JM; Aaron S; Marciniuk DD; Maltais F; Buist AS; O'Donnell DE; Sin DD;
    PLoS One; 2013; 8(3):e58932. PubMed ID: 23554960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
    Müller V; Gálffy G; Orosz M; Kováts Z; Odler B; Selroos O; Tamási L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():93-101. PubMed ID: 26834466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.
    Barjaktarevic IZ; Buhr RG; Wang X; Hu S; Couper D; Anderson W; Kanner RE; Paine Iii R; Bhatt SP; Bhakta NR; Arjomandi M; Kaner RJ; Pirozzi CS; Curtis JL; O'Neal WK; Woodruff PG; Han MK; Martinez FJ; Hansel N; Wells JM; Ortega VE; Hoffman EA; Doerschuk CM; Kim V; Dransfield MT; Drummond MB; Bowler R; Criner G; Christenson SA; Ronish B; Peters SP; Krishnan JA; Tashkin DP; Cooper CB;
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2927-2938. PubMed ID: 31908441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.
    Calverley PM; Albert P; Walker PP
    Lancet Respir Med; 2013 Sep; 1(7):564-73. PubMed ID: 24461617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.
    Fortis S; Comellas A; Make BJ; Hersh CP; Bodduluri S; Georgopoulos D; Kim V; Criner GJ; Dransfield MT; Bhatt SP;
    Ann Am Thorac Soc; 2019 Jul; 16(7):826-835. PubMed ID: 30908927
    [No Abstract]   [Full Text] [Related]  

  • 10. A New Bronchodilator Response Grading Strategy Identifies Distinct Patient Populations.
    Hansen JE; Dilektasli AG; Porszasz J; Stringer WW; Pak Y; Rossiter HB; Casaburi R
    Ann Am Thorac Soc; 2019 Dec; 16(12):1504-1517. PubMed ID: 31404502
    [No Abstract]   [Full Text] [Related]  

  • 11. Bronchodilator response of advanced lung function parameters depending on COPD severity.
    Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.
    Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M
    Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010.
    Tilert T; Dillon C; Paulose-Ram R; Hnizdo E; Doney B
    Respir Res; 2013 Oct; 14(1):103. PubMed ID: 24107140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease.
    Albert P; Agusti A; Edwards L; Tal-Singer R; Yates J; Bakke P; Celli BR; Coxson HO; Crim C; Lomas DA; Macnee W; Miller B; Rennard S; Silverman EK; Vestbo J; Wouters E; Calverley P
    Thorax; 2012 Aug; 67(8):701-8. PubMed ID: 22696176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bronchodilator response in residual volume in irreversible airway obstruction.
    Balestra AM; Bingisser RB; Chhajed PN; Tamm M; Leuppi JD
    Swiss Med Wkly; 2008 May; 138(17-18):251-5. PubMed ID: 18481230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [FEV1 after three years of observation in patients with bronchial asthma and patients with chronic obstructive pulmonary disease].
    Zagdańska R; Grzelewska-Rzymowska I
    Pneumonol Alergol Pol; 2005; 73(2):142-7. PubMed ID: 16756143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the response to a bronchodilator in patients with airflow obstruction and lung cancer.
    Ueda K; Murakami J; Tanaka T; Yoshida K; Kobayashi T; Hamano K
    J Surg Res; 2018 Aug; 228():20-26. PubMed ID: 29907212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
    Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD.
    Tashkin DP; Li N; Halpin D; Kleerup E; Decramer M; Celli B; Elashoff R
    Respir Med; 2013 Dec; 107(12):1904-11. PubMed ID: 23972968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study.
    Tan WC; Vollmer WM; Lamprecht B; Mannino DM; Jithoo A; Nizankowska-Mogilnicka E; Mejza F; Gislason T; Burney PG; Buist AS;
    Thorax; 2012 Aug; 67(8):718-26. PubMed ID: 22544896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.